Background The aim of the study was to compare the cost effectiveness of immediate diagnosis and treatment of mild dyskaryosis compared with the usual policy of cytological surveillance. 
Although immediate referral to colposcopy may be more effective than surveillance, it is important, if health care resources are to be used efficiently, to estimate the relative cost effectiveness of immediate referral compared with surveillance. Ideally, such a comparison should be made within the context of a randomized trial. The aim of this paper, therefore, is to estimate the relative cost effectiveness of immediate referral to colposcopy within the context of the Aberdeen Birthright randomized trial. 3 
Methods
The patients and methods of the Aberdeen Birthright study of mild and moderate dyskaryosis have been described previously.
Introduction
The management of a woman with a single mildly dyskaryotic smear remains controversial. Two management policies have been advocated for such women. The first strategy, which forms the basis of the most recent clinical guidelines, 1 recommends cytological surveillance by repeat cytology at six months and referral to colposcopy only if the dyskaryosis persists. An alternative to surveillance is immediate referral for colposcopy. This second approach has been the strategy of choice for many colposcopy clinics in the United Kingdom, 2 and a recent randomized clinical trial has shown the policy of immediate referral to colposcopy to be more effective in detecting cases of cervical intraepithelial neoplasia grade III (CIN III) than management by surveillance.
for those women randomized to surveillance. Cervical smears were classified according to the British Society for Clinical Cytology terminology following the guidelines for adequacy of cervical smears. 4 In this paper we consider the cost effectiveness of two strategies for the management of women with mild dyskaryosis: first, women who were randomized to the immediate diagnosis and treatment group; and second, women who were randomized to the 24-month surveillance group. The outcome measure used is the number of cases of CIN m detected in each group.
Cost estimation
This paper is concerned purely with health service costs and we have not measured the changes in private costs borne by the women and their families as a result of the different management policies.
Costs were calculated for a number of 'building blocks' which were then used to calculate the total costs for different packages of care. These building blocks included:
(1) costs of cervical smears in general practice; (2) costs of cytological assessment of cervical smears; (3) costs of an assessment visit to the colposcopy clinic (including a smear); (4) costs of large loop excision of the transformation zone at the colposcopy clinic; (5) costs of a follow-up visit to the colposcopy clinic (including a smear); (6) costs of histological assessment of samples taken at the colposcopy clinic.
In Table 1 we show the methods of estimating the 'building block' costs, which included observational work and interviews. Staff costs were based on the midpoint of the appropriate salary scale and included local on-costs (such as superannuation payments). Cost figures were supplied by the local health board Finance Department, and by relevant suppliers and local budget holders. Using these building blocks, the costs of an assessment visit and the costs of a treatment visit were calculated to give the cost of a 'see and treat' visit. This combined cost included only one amount for running costs and did not include a punch biopsy.
Women in the immediate diagnosis and treatment group were costed for two colposcopy visits. First, there was an initial treatment visit which included a repeat cervical smear (it was assumed that the smears were reported by a medical officer) and a colposcopic assessment followed by a biopsy using a large loop excision of the transformation zone (LLETZ). On the second visit, there was a colposcopic assessment and a repeat cervical smear.
In the randomized trial women in the surveillance group were expected to attend the colposcopy clinic every six months, where a repeat smear was undertaken. However, a more pragmatic management policy is for such women to have their repeat smears undertaken within the community and it is the cost of such community smears which have been used in this analysis. For women in the surveillance group three outcomes were envisaged: (1) completion of 24 months surveillance without dyskaryosis recurrence; (2) default from surveillance; (3) recurrent dyskaryosis leading to colposcopy, diagnosis and treatment.
Cost data were collected in 1989 and these were adjusted to the 1994 prices index using the Scottish Health Services specific price and pay index (Scottish Office, personal communication). All costs occurring in the future were discounted at 6 per cent.
Statistics
For the immediate treatment group the costs had no variance as all women had the same treatment; therefore, there are no confidence intervals presented around this cost estimate. However, for the surveillance group the cost data were variable and for this group a 95 per cent confidence interval (CI) for the costs was estimated. For the cost effectiveness ratios the appropriate CIs for the two groups were calculated as follows. In both groups the CIs for the number of cases detected were calculated. For the immediate treatment group the total cost of treatment was divided by the upper and lower confidence limits for the number of cases detected, to provide an upper and lower 95 per cent cost effectiveness confidence interval. However, as both the costs and effect data in the surveillance group were variable, a different approach was required.
Non-parametric bootstrapping methods 5 " 7 were used to calculate the appropriate 95 per cent CI for the cost effectiveness ratio for the surveillance group. Using the bootstrap approach, repeated random samples, known as resamples, of the same size as the original sample are drawn with replacement from the data (i.e. individual observations from the sample can be selected more than once). For example, for ten data points numbered 1-10, a possible resample could include the data points 1, 5, 3,10,6, 6, 9, 5, 7, 2. As such, some observations from the original sample will be included in a resample more than once whereas other observations will not be included at all. The statistic under examination (i.e. the mean cost per case detected in our study) is then estimated from each resample. The number of bootstrap resamples calculated should be at least 1000 for the construction of confidence intervals. 6 Because of the interdependence between cost and whether a case was detected, the cost and outcome data for each woman were resampled together. The resulting 1000 estimates were then used to construct an empirical distribution of the mean cost per case, from which confidence limits were calculated. The confidence intervals reported in this paper are known as bias corrected (BC) percentile bootstrap confidence intervals. A more detailed account of bootstrapping can be found in the monograph by Mooney and Duval.
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Results
One hundred and forty-five women with mild dyskaryosis were allocated to the immediate diagnosis and treatment group and 158 were allocated to the two-year surveillance group. For the immediate diagnosis and treatment group, there were no defaulters (as treatment was given on the initial visit) and 66 (46 per cent) cases of CIN in were detected. In the surveillance group, 36 women eventually defaulted and 82 women were referred for colposcopy, of whom 43 had CIN HI (27 per cent of the total sample). The unit costs for the colposcopy clinic are detailed in Table 2 and are based on a combination of the mean staffing time, material, running and laboratory costs observed during 50 consecutive colposcopy appointments. For the immediate treatment group when follow-up costs were included, the resulting cost estimate was £82.02 per woman.
For the surveillance group, repeat cervical smears are undertaken in the community and these costs are detailed in The cost per case of CIN III detected in the immediate treatment group was lower than in the surveillance group. To consider a policy change from surveillance to immediate diagnosis and treatment, however, the extra costs incurred must be related to the extra benefits produced by such a change. We therefore undertook a marginal analysis. 8 This was undertaken as follows. First, as there were different numbers in each treatment group, we needed to estimate a surveillance cost for 
Discussion

Effectiveness
Any management policy of women with mild dyskaryosis should aim to be safe and cost effective. The most recent recommendation by the United Kingdom Co-ordinating Committee suggested cytological surveillance for women with referral to colposcopy only if the cytological abnormality persisted or deteriorated. This policy is only sensible if there is a low prevalence of high-grade lesions at the outset and if clear evidence exists of significant cytological regression for the majority of cases. Otherwise, many women with significant pathology will have their diagnosis and treatment delayed whereas others may default from surveillance with a risk of progressing to invasive disease. Furthermore, women whose cytology does not revert back to normal will ultimately be referred to colposcopy anyway. The clinical paper resulting from this study showed that significant numbers of women with a mildly dyskaryotic smear had CIN HI (35 per cent) . 3 In addition, only a minority (29 per cent) of women with dyskaryosis reverted back to normal. Finally, a quarter of all women defaulted to follow-up by two years. 3 
Cost effectiveness
We chose CIN HI as our outcome measure because its natural history is known 9 and because it is considered a robust diagnosis. 10 In this study we have taken a conservative view of the costs and benefits accruing to the immediate colposcopy policy. The prime cost and benefit omission is the eventual cost of treating the defaulters and their loss of health if the undetected cases of CIN HI proceed to invasive cancer. Failure to account for these costs will bias our results against immediate diagnosis and treatment.
Although the clinical evaluation of immediate diagnosis and treatment suggested that this was the most effective strategy, it is clear from the results in this paper that it entails greater resource use. Indeed, immediate diagnosis and treatment is associated with an approximate 50 per cent increase in total cost. However, set against this increased cost is substantially more benefit in the form of an 69 per cent increase in the numbers of CIN III detected. This result contrasts sharply with a recent decision analysis which suggested that immediate referral to colposcopy could be financially less expensive than surveillance.'' However, in that analysis it was assumed that a colposcopic examination was equivalent in cost to six smears, whereas our results suggest that a colposcopic treatment is equivalent in cost to 12 smears. This finding shows the need to conduct an economic analysis alongside clinical trials, as economic or decision analytic modelling, although useful, cannot be relied on completely to capture all the costs incurred by a change in health care policy. Despite immediate diagnosis and treatment producing lower average and marginal cost effectiveness ratios compared with surveillance, it cannot be automatically concluded that it is more cost effective. This judgement is dependent upon consideration of the wider implications of introducing such a policy within the National Health Service; i.e. consideration of the opportunity cost (the health benefit foregone) of allocating more resources from elsewhere in the health care budget to immediate diagnosis and treatment. If it is judged that resources taken from elsewhere, for instance by increasing the screening interval for low-risk women, loses less health benefit than is gained by immediate diagnosis and treatment, then such a policy will be cost effective.
Our use of confidence intervals for cost effectiveness ratios deserves comment as, to date, few cost effectiveness ratios, when both costs and effects have variance, have been reported in the literature. 12 There may be three reasons for this. First, in many instances, costs do not have any variance (as in the immediate diagnosis and treatment groups) and therefore simply dividing the costs by the appropriate confidence intervals of effects is appropriate. Second, it is only relatively recently that randomized trials have started to include contemporaneous economic evaluations, which increases the likelihood of collecting stochastic cost data. Finally, only the arrival of modem computing power has allowed the relevant statistical calculations, such as the use of bootstrapping, to be undertaken with relative ease.
Conclusion
This study has shown that changing the policy for women with mild dyskaryosis to immediate diagnosis and treatment from that of surveillance will increase costs. However, there is a sharp increase in benefit in the form of cases of CIN III detected. In deciding whether extra resources should be made available for cervical screening, purchasers will have to judge whether more benefit could be obtained elsewhere with the same resources. On the other hand, our research does show that reallocation of existing resources to immediate diagnosis and treatment may result in an overall increase in health.
